Together, we can redefine cancer treatment—and create more hope than ever before.

We are actively expanding our portfolio of oncology assets, collaborating with biotechnology firms, pharmaceutical companies and academic researchers seeking to accelerate development of their first-in-class or global top 3 preclinical assets. Our partnership models and deal structures are flexible and are consistently guided by our core principle that maximum value creation occurs when interests are aligned. Through our capital-efficient model, rigorous clinical trials, and global licensing network, we strive to unlock the best outcome possible for partnered assets.